HCW Biologics reports FY2022 revenue $6.7M, net loss $14.9M; cash $32M

HCW Biologics Inc.

Q4 2022 revenue $1.3M from licensed molecule sale to Wugen; full year $6.7M (nil in prior year).
R&D expenses $9.3M for FY2022 (vs $8.2M), G&A $8.3M (vs $5.2M); net loss $14.9M (vs $12.9M).
Cash, cash equivalents & short-term investments total $32.0M as of Dec 31, 2022; funding sufficient through next 12 months.
Phase 1/1b trials for HCW9218 in solid tumors and advanced pancreatic cancer ongoing; Phase 1 completion targeted in 2023.
CRADA with NCI for Phase 1b/2 pancreatic study; scientific paper on HCW9302 published in Frontiers in Immunology.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HCW Biologics Inc. reported the year ended December 31, 2022 results: revenue $6.7 million.

Period: the year ended December 31, 2022
Revenue: $6.7 million
Result: reported results

Exact text from the filing

Revenues for the year ended December 31, 2021 and 2022 were nil and $6.7 million, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HCW Biologics Inc. reported the fourth quarter ended December 31, 2022 results: revenue $1.3 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $1.3 million
Result: reported results

Exact text from the filing

Revenues for the fourth quarter ended December 31, 2021 and 2022 were nil and $1.3 million, respectively.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-010313

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.